In Project 3, we propose to exploit our understanding of cancer biology to develop assays for compounds that could lead to more effective and less toxic chemotherapeutic agents. We propose two general approaches to identifying new agents. First, we will develop assays that are not targeted to a specific cellular pathway, but instead search for general perturbations in cell growth, division, morphology, or embryonic development. By not specifying that agents act through a specific biological mechanism, this approach may provide the greatest change of identifying potential lead compounds that act through a novel mechanism, as many potential cellular targets are screened simultaneously. To complement this open-ended approach, we also propose to exploit our current understanding of cancer biology and basic cell biology to design assays that target specific proteins or biological mechanisms whose pharmacologic inhibition would be expected to be toxic to proliferating cells. Selected targets include gamma-tubulin, the cyclin B proteolysis system, and a mitotic kinesin (KCM) present in dividing cells, but not neurons. Inhibitors of the latter protein should lack the neurotoxicity seen in other tubulin inhibitors. We will also design assays to identify compounds that sensitize cancer cells to current chemotherapeutic agents and ionizing radiation. This will include a screen for inhibitors of the spindle assembly checkpoint, which may make cells more sensitive to anti- mitotic agents, and a screen for inhibitors of DNA glycosylases, which should make cells more sensitive to chemotherapies that damage DNA. These assays will make use of the small molecule libraries developed in Project 1. An important goal is to adapt these assays to the nanodroplet format being developed in Project 2, increasing the efficiency of the screening process. We will also utilize the target identification strategies being developed in Project 2 to identify the protein targets of small molecules for which the target has not been determined by the nature of the assay. Small molecules with potential activity will be resynthesized by the Synthetic Chemistry Core (Core B). The synthetic chemistry core will also support the generation of structural derivatives of the lead compound once its activity is confirmed following resynthesis. The Administrative Core A will coordinate the efforts of this Project with the work of Projects 1 and 2, and will provide administrative assistance and financial oversights.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA078048-01
Application #
6269927
Study Section
Project Start
1998-05-15
Project End
1999-02-28
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Shi, Jue; Mitchison, Timothy J (2017) Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocr Relat Cancer 24:T83-T96
Bradner, James E; West, Nathan; Grachan, Melissa L et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238-243
Gatlin, Jesse C; Matov, Alexandre; Danuser, Gaudenz et al. (2010) Directly probing the mechanical properties of the spindle and its matrix. J Cell Biol 188:481-9
Tolopko, Andrew N; Sullivan, John P; Erickson, Sean D et al. (2010) Screensaver: an open source lab information management system (LIMS) for high throughput screening facilities. BMC Bioinformatics 11:260
Kawada, Junichi; Zou, Ping; Mazitschek, Ralph et al. (2009) Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 284:17102-9
Gatlin, Jesse C; Matov, Alexandre; Groen, Aaron C et al. (2009) Spindle fusion requires dynein-mediated sliding of oppositely oriented microtubules. Curr Biol 19:287-96
Huang, Hsiao-Chun; Shi, Jue; Orth, James D et al. (2009) Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16:347-58
Birmingham, Amanda; Selfors, Laura M; Forster, Thorsten et al. (2009) Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 6:569-75
Wang, Qiu; Schreiber, Stuart L (2009) Copper-mediated amidation of heterocyclic and aromatic C-H bonds. Org Lett 11:5178-80
Tsui, Melody; Xie, Tiao; Orth, James D et al. (2009) An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor. PLoS One 4:e7339

Showing the most recent 10 out of 54 publications